Skip to content

Biodesix, Inc. BDSX Free cash flow yield

Free cash flow yield at other companies

NeoGenomics logo
NeoGenomicsNEO
-2.7%
Veracyte logo
VeracyteVCYT
6.1%+2.7pp
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-1.4%-0.7pp
Personalis, Inc. logo
Personalis, Inc.PSNL
-12.7%-1.7pp
Guardant Health logo
Guardant HealthGH
-2%-0.8pp
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
-6%

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Calculated from Biodesix, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s free cash flow yield?
Biodesix, Inc. (BDSX) reported free cash flow yield of -18% in Q1 2026.
How has Biodesix, Inc.'s free cash flow yield changed year-over-year?
Biodesix, Inc.'s free cash flow yield increased by 63.4% year-over-year, from -49.3% to -18%.
What is the long-term trend for Biodesix, Inc.'s free cash flow yield?
Over 5 years (2020 to 2025), Biodesix, Inc.'s free cash flow yield has grown at a 59.4% compound annual growth rate (CAGR), from -4.3% to -44.8%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.